育龄期心房颤动与心房扑动的性别差异:表现、治疗与结局
结果显示,与男性相比,育龄期女性症状负担更重、阵发性房颤比例更高,接受节律控制治疗的比例更低,且消融并发症更多。抗凝与抗心律失常药物使用无显著性别差异,但女性存在更多抗凝禁忌。
要点
- 育龄期女性房颤或房扑患者症状更重、阵发性房颤比例更高。
- 女性接受节律控制治疗的比例低于男性,房颤消融并发症发生率更高。
- 抗凝与抗心律失常药物使用无性别差异,但女性抗凝禁忌更多。
核心结论
- 育龄期女性房颤或房扑患者接受节律控制干预的可能性更低,消融并发症更多,抗凝禁忌也更多。
研究设计与样本
- 主要暴露因素为性别,主要结局包括抗凝处方和节律控制策略,并使用多变量逻辑回归校正年龄、种族、保险和贫血等协变量。
主要发现
- 女性症状更多,阵发性房颤比例更高(57.7% vs. 49.9%,p<0.001),男性持续性房颤比例更高(19.9% vs. 11.6%,p<0.001)。
- 女性CHA2DS2VASc评分显著高于男性(2.3±1.2 vs. 1.4±1.2,p<0.001)。
- 女性接受节律控制治疗总体可能性低9%至15%(校正OR 0.91,95%CI 0.83–0.99),差异主要由房颤消融和电复律驱动。
- 接受消融的女性并发症发生率更高(3.7% vs. 1.9%,p=0.01),且更可能存在抗凝相对或绝对禁忌(9.0% vs. 7.2%,p<0.001)。
关键数值与推荐
- 女性阵发性房颤比例57.7%,男性49.9%,p<0.001。
- 男性持续性房颤比例19.9%,女性11.6%,p<0.001。
- 女性CHA2DS2VASc评分2.3±1.2,男性1.4±1.2,p<0.001。
- 女性接受节律控制治疗校正OR 0.91,95%CI 0.83–0.99。
- 女性消融并发症率3.7%,男性1.9%,p=0.01;女性抗凝禁忌比例9.0%,男性7.2%,p<0.001。
临床怎么用
- 对育龄期房颤或房扑女性应更积极评估症状负担和抗凝禁忌,并关注节律控制策略的适用性。
- 为年轻女性房颤患者制定消融或电复律方案时,需警惕更高的并发症风险和抗凝禁忌情况。
局限性
- 研究为注册研究设计,可能存在未测量的混杂因素影响性别与治疗及结局的关联估计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Younger women with atrial fibrillation and flutter (AF/AFL) presented with greater symptom burden and more paroxysmal AF than men. Women had lower rates of treatment with rhythm control strategies and more AF ablation complications. We found no differences in anticoagulant or antiarrhythmic use, while women had more contraindications to anticoagulation. ABSTRACT Background Atrial fibrillation/flutter (AF/AFL) are increasingly seen in reproductive-aged adults, yet AF/AFL guidelines are largely based on older populations. Sex differences in this age group remain poorly defined. In this study, we examined sex-based disparities in the presentation, management, and outcomes among reproductive-aged adults with AF/AFL. Methods Using the Get With The Guidelines–Atrial Fibrillation national registry, we included adults (18–50 years) with AF/AFL who were prospectively enrolled from May 2013 to March 2024. The primary exposure was sex and primary outcomes included anticoagulant prescription and rhythm control strategies (cardioversion, AF ablation, or antiarrhythmic therapy). Multivariable logistic regression estimated associations between sex and outcomes, adjusting for covariates including age, race and ethnicity, insurance, and anemia. Results Among 14 301 patients with mean age 42.3 ± 7.3 years, women were more symptomatic and had more paroxysmal AF (57.7% vs. 49.9%, p < 0.001), while men had more persistent AF (19.9% vs. 11.6%, p < 0.001). CHA2DS2VASc scores were significantly higher in women (2.3 ± 1.2 vs. 1.4 ± 1.2 in men, p < 0.001). Despite similar use of antiarrhythmic drugs and anticoagulation, women were 9%–15% less likely to receive rhythm-control therapies overall (adjusted OR 0.91, 95% CI 0.83–0.99), driven by differences in AF ablation and cardioversion. For both sexes, the proportion of patients undergoing ablation increased while those undergoing cardioversion decreased significantly over time (all p < 0.001). Women undergoing AF ablation experienced more complications (3.7% vs. 1.9%, p = 0.01) and were more likely to have relative or absolute contraindications to anticoagulation (9.0% vs. 7.2%, p < 0.001). Conclusions In a large US registry, reproductive-aged women with AF/AFL were less likely to receive rhythm-control interventions, experienced more ablation complications, and had more anticoagulation contraindications. These findings highlight persistent sex-based disparities in the management and outcomes of young adults with AF/AFL, underscorin
引用
- Journal of Cardiovascular Electrophysiology:Sex Disparities in Atrial Fibrillation and Atrial Flutter Presentation, Treatment, and Outcomes in Reproductive‐Aged Individuals
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。